Siren L.L.C. Makes New $10.15 Million Investment in Rezolute, Inc. $RZLT

Siren L.L.C. acquired a new position in Rezolute, Inc. (NASDAQ:RZLT) during the first quarter, HoldingsChannel reports. The institutional investor acquired 3,328,287 shares of the company’s stock, valued at approximately $10,151,000.

A number of other large investors have also recently made changes to their positions in the business. Knott David M Jr raised its holdings in shares of Rezolute by 8.8% during the first quarter. Knott David M Jr now owns 370,000 shares of the company’s stock valued at $1,128,000 after acquiring an additional 30,000 shares in the last quarter. Sei Investments Co. lifted its stake in Rezolute by 286.8% in the first quarter. Sei Investments Co. now owns 146,576 shares of the company’s stock worth $447,000 after acquiring an additional 108,679 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Rezolute by 273.7% in the first quarter. Dimensional Fund Advisors LP now owns 530,229 shares of the company’s stock valued at $1,617,000 after acquiring an additional 388,346 shares in the last quarter. AlphaCentric Advisors LLC boosted its holdings in Rezolute by 6.2% in the first quarter. AlphaCentric Advisors LLC now owns 71,227 shares of the company’s stock valued at $217,000 after acquiring an additional 4,171 shares in the last quarter. Finally, Jennison Associates LLC bought a new stake in Rezolute in the first quarter valued at $10,489,000. 82.97% of the stock is currently owned by institutional investors.

Rezolute Stock Up 6.2%

NASDAQ RZLT opened at $5.31 on Friday. Rezolute, Inc. has a twelve month low of $1.07 and a twelve month high of $11.46. The firm has a market capitalization of $511.30 million, a PE ratio of -6.48 and a beta of 0.54. The stock’s 50 day moving average is $4.37 and its 200 day moving average is $3.56.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. On average, research analysts anticipate that Rezolute, Inc. will post -0.69 earnings per share for the current year.

Analyst Upgrades and Downgrades

RZLT has been the subject of several research reports. Citigroup upgraded shares of Rezolute from a “market perform” rating to an “outperform” rating in a report on Wednesday, June 3rd. Zacks Research lowered shares of Rezolute from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Rezolute in a research report on Tuesday, June 2nd. Citizens Jmp raised shares of Rezolute from a “market perform” rating to an “outperform” rating and set a $11.00 price target for the company in a research note on Wednesday, June 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Rezolute in a report on Friday, July 17th. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Rezolute has an average rating of “Moderate Buy” and a consensus price target of $9.38.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.